Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial

Vaccine

Volumn 33, Issue 48, 2015, Pages 6816-6822

  Anand, Abhijeet ^a   Zaman, K ^b   Estívariz, Concepción F ^a   Yunus, Mohammad ^b   Gary, Howard E ^a   Weldon, William C ^a   Bari, Tajul I ^c   Steven Oberste, M ^a   Wassilak, Steven G ^a   Luby, Stephen P ^d   Heffelfinger, James D ^a,b   Pallansch, Mark A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^c WHO Bangladesh   (Bangladesh)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Inactivated polio vaccine; Oral polio vaccine; Polio immunogenicity; Priming

Indexed keywords

POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; BANGLADESH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN POLIOVIRUS 1; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MICRONEEDLE; MUCOSAL IMMUNITY; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROPREVALENCE; SEROTYPE; VACCINATION; BLOOD; DEVICES; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; POLIOMYELITIS; TREATMENT OUTCOME;

ANTIBODIES, VIRAL; BANGLADESH; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INJECTIONS, INTRADERMAL; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; TREATMENT OUTCOME;

EID: 84949786756     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.039     Document Type: Article

References (27)

1. Sutter R.W., Kew O.M., Cochi S.L., Aylward R.B. Poliovirus vaccine-live. Vaccines 2012, 1576. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
2. Centers for Disease Control Prevention Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkl Rep 2001, 50(March 12):222-224.
3. The Global Polio Eradication Initiative Circulating vaccine-derived poliovirus 2014, Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccinederivedpoliovirus.aspx.
4. World Health Organization Meeting of the strategic advisory group of experts on immunization april 2013 - conclusions and recommendations. Wkly Epidemiol Rec 2013, 88:201-216.
5. World Health Organization Meeting of the strategic advisory group of experts on immunization october 2014 - conclusions and recommendations. Wkly Epidemiol Rec 2014, 89(50):561-576.
6. Anand A., Pallansch M.A., Estivariz C.F., Gary H., Wassilak S.G. Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys. J Infect Dis 2014, 210(November (Suppl. 1)):S465-S474.
7. Resik S., Tejeda A., Sutter R.W., Diaz M., Sarmiento L., Alemani N., et al. Priming after a fractional dose of inactivated poliovirus vaccine. N. Engl J Med 2013, 368(January (5)):416-424.
8. World Health Organization Meeting of the strategic advisory group of experts on immunization, april 2012 - conclusions and recommendations, The Weekly Epidemiological Record 2012, 201-216. Geneva, Switzerland.
9. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27(January (3)):454-459.
10. Hung I.F., Levin Y., To K.K. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine 2012, 30(April (17)):2707-2708.
11. Hung I.F., Levin Y., To K.K., Chan K.H., Zhang A.J., Li P., et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012, 30(October (45)):6427-6435.
12. Levin Y., Kochba E., Kenney R. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same?. Vaccine 2014, 32(July (34)):4249-4252.
13. World Health Organization Polio laboratory manual 2004, Geneva, Switzerland.
14. Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201(May (9)):1344-1352.
15. Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010, 376(November (9753)):1682-1688.
16. Zaman K., Sack D.A., Yunus M., Arifeen S.E., Podder G., Azim T., et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009, 27(February (9)):1333-1339.
17. The Cuba IPV Study Collaborative Group Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007, 356(April (15)):1536-1544.
18. Albrecht P., Enterline J.C., Boone E.J., Klutch M.J. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J Biol Stand 1983, 11(April (2)):91-97.
19. Reed G.F., Meade B.D., Steinhoff M.C. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 1995, 96(September (3 Pt 2)):600-603.
20. Grassly N.C., Wenger J., Durrani S., Bahl S., Deshpande J.M., Sutter R.W., et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007, 369(April (9570)):1356-1362.
21. O'Reilly K.M., Durry E., ul Islam O., Quddus A., Abid N., Mir T.P., et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001-11: a retrospective analysis. Lancet 2012, 380(August (9840)):491-498.
22. World Health Organization Collaborative Study Group Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. J Infect Dis 1995, 171(May 5):1097-1106.
23. WHO Collaborative Study Group Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia Oman, and Thailand. Bull World Health Org 1996, 74(3):253-268.
24. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13(September-October (5)):926-939.
25. Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamir E., Shaban M.M., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362(June (25)):2351-2359.
26. Modlin J.F., Halsey N.A., Thoms M.L., Meschievitz C.K., Patriarca P.A. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis 1997, 175(February (Suppl. 1)):S228-S234.
27. Fine P.E., Carneiro I.A. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999, 150(November (10)):1001-1021.